Procept BioRobotics

CA - San JoseBiotechnology12 H-1B visas (FY2023)

Focus: Procept BioRobotics is a medical robotics company specializing in Aquablation therapy, a waterjet-based robotic system for minimally invasive treatment of benign prostatic hyperplasia and localized prostate cancer. The company operates as a focused device innovator with active clinical development in urology.

Ophthalmology Neurology Oncology

Profile data last refreshed 2h ago · AI intelligence enriched 1w ago

Open Jobs

0-3 this month

Stable — net -3 jobs in 30d

1 added, 4 removed. Backfill posture.

About Procept BioRobotics

AI assessmentNot Hiring

No open roles listed right now. Follow Procept BioRobotics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

14 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AQUABEAM System followed by catheter without hemostatic agent

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT04308070Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia III

N/A

Help build intelligence for Procept BioRobotics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pioneering medical robotics platform with 14 active clinical trials demonstrating commercial traction in high-prevalence urology market
100% H1B approval rate (12/12 approvals in 2023) signals strong visa sponsorship and international talent recruitment capacity
Device-based business model typically offers more stable, recurring revenue streams than early-stage pharma with fewer pipeline attrition risks

Watch Out For

Only 4 active job openings across entire organization suggests limited near-term hiring and narrow career path options
All recruiting concentrated in single RAQA department indicates minimal functional diversity and unclear growth trajectory across commercial, clinical, or R&D

Generated by Claude from Procept BioRobotics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AquaBeam System

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT03167294AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia

N/A

UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT04658056UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

N/A

AquaBeam System

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT03125863Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia

N/A

AquaBeam System

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT03125889Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II

N/A

Robotic Waterjet Treatment

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT06051942PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

N/A

Aquablation therapy

BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms

N/A

Clinical Trials (1)

NCT04801381WATER III: Aquablation vs. Transurethral Laser Enucleation of Large Prostates (80 - 180mL) in Benign Prostatic Hyperplasia

N/A

Aquablation

Benign Prostatic Hyperplasia (BPH)

N/A

Clinical Trials (1)

NCT03123250Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II

N/A

AQUABEAM Robotic System

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT05157529AQUABEAM® Robotic System and Ultrasound Accessories

N/A

AQUABEAM System

Benign Prostatic Hyperplasia (BPH)

N/A

Clinical Trials (1)

NCT02505919Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

N/A

Aquablation

BPH

N/A

Clinical Trials (1)

NCT02974751Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

N/A

Robotic Waterjet Treatment

Localized Prostate Cancer

N/A

Clinical Trials (1)

NCT06054867PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System

N/A

AQUABEAM System

Benign Prostatic Hyperplasia (BPH)

N/A

Clinical Trials (1)

NCT03191734French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

N/A

Aquablation Therapy

Localized Prostate Cancer

N/A

Clinical Trials (1)

NCT06651632WATER IV Prostate Cancer

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 14 clinical trials

Top TAs: Oncology

H-1B (2023): 12 approvals

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

3 pipeline

Marketed

Pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub